Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities

Melanoma claims annually more than 20,000 lives in Europe and is an important public health burden through its continuously increasing incidence and with its high mortality, costs, and complexity of care in advanced stages. Epidemiological surveillance is indispensable for the research into its cau...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Ana-Maria Forsea
Formato: article
Lenguaje:EN
Publicado: Mattioli1885 2020
Materias:
Acceso en línea:https://doaj.org/article/d5ee0f350de04fb3873ddebf59e79e34
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d5ee0f350de04fb3873ddebf59e79e34
record_format dspace
spelling oai:doaj.org-article:d5ee0f350de04fb3873ddebf59e79e342021-11-17T08:28:35ZMelanoma Epidemiology and Early Detection in Europe: Diversity and Disparities10.5826/dpc.1003a332160-9381https://doaj.org/article/d5ee0f350de04fb3873ddebf59e79e342020-07-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1074https://doaj.org/toc/2160-9381 Melanoma claims annually more than 20,000 lives in Europe and is an important public health burden through its continuously increasing incidence and with its high mortality, costs, and complexity of care in advanced stages. Epidemiological surveillance is indispensable for the research into its causes, new prognostic markers, and innovative therapies, as well as for the building of efficient cancer control plans. However, important differences in the sources and availability of accurate epidemiological data exist among European countries and regions, contributing to a heterogeneous picture with 20-fold differences in the reported national melanoma incidence rates, divergent mortality trends, and solid disparities in survival across the Continent. Countries in the eastern half of Europe report the lowest incidence rates, but high case fatality, persisting and increasing mortality, a higher proportion of thicker tumors and late diagnosis, and lower survival rates. They are the least well equipped with quality cancer registration and reporting, and they lag behind in efficient cancer control plans implementation. This review highlights the main differences in melanoma epidemiology across Europe, together with an insight into their underlying causes in the areas of melanoma registration, early diagnosis, and prevention. These differences should be acknowledged and understood by physicians, researchers, and all stakeholders involved in improving melanoma care and outcomes, as no one-size-fits-all solution can tackle the melanoma problem in Europe. Instead, there is a need for nuanced strategies, adapted to the heterogeneous national and regional contexts, that would build on European diversity to eliminate the outcome disparities. Ana-Maria ForseaMattioli1885articlemelanomaepidemiologyearly detectiondisparitiesEuropeDermatologyRL1-803ENDermatology Practical & Conceptual, Vol 10, Iss 3 (2020)
institution DOAJ
collection DOAJ
language EN
topic melanoma
epidemiology
early detection
disparities
Europe
Dermatology
RL1-803
spellingShingle melanoma
epidemiology
early detection
disparities
Europe
Dermatology
RL1-803
Ana-Maria Forsea
Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities
description Melanoma claims annually more than 20,000 lives in Europe and is an important public health burden through its continuously increasing incidence and with its high mortality, costs, and complexity of care in advanced stages. Epidemiological surveillance is indispensable for the research into its causes, new prognostic markers, and innovative therapies, as well as for the building of efficient cancer control plans. However, important differences in the sources and availability of accurate epidemiological data exist among European countries and regions, contributing to a heterogeneous picture with 20-fold differences in the reported national melanoma incidence rates, divergent mortality trends, and solid disparities in survival across the Continent. Countries in the eastern half of Europe report the lowest incidence rates, but high case fatality, persisting and increasing mortality, a higher proportion of thicker tumors and late diagnosis, and lower survival rates. They are the least well equipped with quality cancer registration and reporting, and they lag behind in efficient cancer control plans implementation. This review highlights the main differences in melanoma epidemiology across Europe, together with an insight into their underlying causes in the areas of melanoma registration, early diagnosis, and prevention. These differences should be acknowledged and understood by physicians, researchers, and all stakeholders involved in improving melanoma care and outcomes, as no one-size-fits-all solution can tackle the melanoma problem in Europe. Instead, there is a need for nuanced strategies, adapted to the heterogeneous national and regional contexts, that would build on European diversity to eliminate the outcome disparities.
format article
author Ana-Maria Forsea
author_facet Ana-Maria Forsea
author_sort Ana-Maria Forsea
title Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities
title_short Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities
title_full Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities
title_fullStr Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities
title_full_unstemmed Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities
title_sort melanoma epidemiology and early detection in europe: diversity and disparities
publisher Mattioli1885
publishDate 2020
url https://doaj.org/article/d5ee0f350de04fb3873ddebf59e79e34
work_keys_str_mv AT anamariaforsea melanomaepidemiologyandearlydetectionineuropediversityanddisparities
_version_ 1718425831287554048